Hainan Shuangcheng Pharmaceut (002693) - Total Liabilities
Based on the latest financial reports, Hainan Shuangcheng Pharmaceut (002693) has total liabilities worth CN¥396.21 Million CNY (≈ $57.98 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hainan Shuangcheng Pharmaceut - Total Liabilities Trend (2009–2025)
This chart illustrates how Hainan Shuangcheng Pharmaceut's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Hainan Shuangcheng Pharmaceut to evaluate short-term liquidity relative to the company's equity base.
Hainan Shuangcheng Pharmaceut Competitors by Total Liabilities
The table below lists competitors of Hainan Shuangcheng Pharmaceut ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wuxi Acryl Technology Co Ltd
SHG:603722
|
China | CN¥262.59 Million |
|
Bradespar S.A
SA:BRAP3
|
Brazil | R$46.54 Million |
|
United States Cellular Corporation
NYSE:USM
|
USA | $2.38 Billion |
|
Temple & Webster Group Ltd
AU:TPW
|
Australia | AU$152.07 Million |
|
Zhejiang Sf Oilless Bearing Co Ltd
SHE:300817
|
China | CN¥259.79 Million |
|
Hefei Lifeon Pharmaceutical Co Ltd
SHE:003020
|
China | CN¥663.27 Million |
|
Sunrise Energy Metals Ltd
AU:SRL
|
Australia | AU$1.37 Million |
|
Capital Bancorp
NASDAQ:CBNK
|
USA | $3.40 Billion |
Liability Composition Analysis (2009–2025)
This chart breaks down Hainan Shuangcheng Pharmaceut's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Hainan Shuangcheng Pharmaceut.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.95 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hainan Shuangcheng Pharmaceut's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hainan Shuangcheng Pharmaceut (2009–2025)
The table below shows the annual total liabilities of Hainan Shuangcheng Pharmaceut from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥405.25 Million ≈ $59.30 Million |
+8.86% |
| 2024-12-31 | CN¥372.26 Million ≈ $54.47 Million |
+30.34% |
| 2023-12-31 | CN¥285.60 Million ≈ $41.79 Million |
-13.47% |
| 2022-12-31 | CN¥330.08 Million ≈ $48.30 Million |
+14.69% |
| 2021-12-31 | CN¥287.80 Million ≈ $42.11 Million |
-6.97% |
| 2020-12-31 | CN¥309.37 Million ≈ $45.27 Million |
+13.44% |
| 2019-12-31 | CN¥272.72 Million ≈ $39.91 Million |
-39.47% |
| 2018-12-31 | CN¥450.56 Million ≈ $65.93 Million |
-26.79% |
| 2017-12-31 | CN¥615.41 Million ≈ $90.05 Million |
+0.49% |
| 2016-12-31 | CN¥612.40 Million ≈ $89.61 Million |
-1.63% |
| 2015-12-31 | CN¥622.56 Million ≈ $91.10 Million |
+1145.41% |
| 2014-12-31 | CN¥49.99 Million ≈ $7.31 Million |
+7.68% |
| 2013-12-31 | CN¥46.42 Million ≈ $6.79 Million |
+13.78% |
| 2012-12-31 | CN¥40.80 Million ≈ $5.97 Million |
+105.79% |
| 2011-12-31 | CN¥19.83 Million ≈ $2.90 Million |
-79.11% |
| 2010-12-31 | CN¥94.92 Million ≈ $13.89 Million |
+376.80% |
| 2009-12-31 | CN¥19.91 Million ≈ $2.91 Million |
-- |
About Hainan Shuangcheng Pharmaceut
Hainan Shuangcheng Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical injections, solid preparations, and raw materials in China and internationally. The company offers products for oncology and immune, alimentary canal, heart and cerebral, and vessels and metabolism. It also provides Bivalirudin, Epitifibatide, and Thymalfaxin for injection; Pre… Read more